Lexeo Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
07/05/2025 13:53
Lexeo Therapeutics Inc LXEO.OQ LXEO.O is expected to show no change in quarterly revenue when it reports results on May 9 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for Lexeo Therapeutics Inc is for a loss of 78 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Lexeo Therapeutics Inc is $21.00, above its last closing price of $3.25. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.81 | -0.78 | Beat | 3.4 | |
| Sep. 30 2024 | -0.66 | -0.68 | -0.89 | Missed | -31.2 |
| Jun. 30 2024 | -0.65 | -0.69 | -0.64 | Beat | 7.4 |
| Mar. 31 2024 | -0.76 | -0.77 | -0.77 | Met | -0.3 |
| Dec. 31 2023 | -0.73 | -0.73 | -0.85 | Missed | -16.8 |
| Sep. 30 2023 | -2.60 | -2.60 | -12.36 | Missed | -375.8 |
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease